Amyloid beta (Aβ or Abeta) is a peptide of 36–43 amino acids that is processed from the Amyloid precursor protein. While best known as a component of amyloid plaques in association with Alzheimer's disease, evidence has been found that Aβ is a highly multifunctional peptide with significant non-pathological activity.[1] Aβ is the main component of deposits found in the brains of patients with Alzheimer's disease
Beta Amyloid ~Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.
The factors driving clinical heterogeneity in Alzheimer's disease are
not well understood. This study assessed the relationship between amyloid
deposition, glucose metabolism and clinical phenotype in Alzheimer's
disease, and investigated how these relate to the involvement of
functional networks. The study included 17 patients with early-onset
Alzheimer's disease (age at onset <65 years), 12 patients with
logopenic variant primary progressive aphasia and 13 patients with
posterior cortical atrophy [whole Alzheimer's disease group: age = 61.5
years (standard deviation 6.5 years), 55% male]. Thirty healthy control
subjects [age = 70.8 (3.3) years, 47% male] were also included. Subjects
underwent positron emission tomography with (11)C-labelled Pittsburgh
compound B and (18)F-labelled fluorodeoxyglucose. All patients met
National Institute on Ageing-Alzheimer's Association criteria for
probable Alzheimer's disease and showed evidence of amyloid
deposition on (11)C-labelled Pittsburgh compound B positron emission
tomography. We hypothesized that hypometabolism patterns would differ
across variants, reflecting involvement of specific functional networks,
whereas amyloid
patterns would be diffuse and similar across variants. We tested these
hypotheses using three complimentary approaches: (i) mass-univariate
voxel-wise group comparison of (18)F-labelled fluorodeoxyglucose and
(11)C-labelled Pittsburgh compound B; (ii) generation of covariance maps
across all subjects with Alzheimer's disease from seed regions of
interest specifically atrophied in each variant, and comparison of these
maps to functional network templates; and (iii) extraction of
(11)C-labelled Pittsburgh compound B and (18)F-labelled
fluorodeoxyglucose values from functional network templates. Alzheimer's
disease clinical groups showed syndrome-specific (18)F-labelled
fluorodeoxyglucose patterns, with greater parieto-occipital involvement
in posterior cortical atrophy, and asymmetric involvement of left
temporoparietal regions in logopenic variant primary progressive
aphasia. In contrast, all Alzheimer's disease variants showed diffuse
patterns of (11)C-labelled Pittsburgh compound B binding, with posterior
cortical atrophy additionally showing elevated uptake in occipital
cortex compared with early-onset Alzheimer's disease. The seed region of
interest covariance analysis revealed distinct (18)F-labelled
fluorodeoxyglucose correlation patterns that greatly overlapped with the
right executive-control network for the early-onset Alzheimer's disease
region of interest, the left language network for the logopenic variant
primary progressive aphasia region of interest, and the higher visual
network for the posterior cortical atrophy region of interest. In
contrast, (11)C-labelled Pittsburgh compound B covariance maps for each
region of interest were diffuse. Finally, (18)F-labelled
fluorodeoxyglucose was similarly reduced in all Alzheimer's disease
variants in the dorsal and left ventral default mode network, whereas
significant differences were found in the right ventral default mode,
right executive-control (both lower in early-onset Alzheimer's disease
and posterior cortical atrophy than logopenic variant primary
progressive aphasia) and higher-order visual network (lower in posterior
cortical atrophy than in early-onset Alzheimer's disease and logopenic
variant primary progressive aphasia), with a trend towards lower
(18)F-labelled fluorodeoxyglucose also found in the left language
network in logopenic variant primary progressive aphasia. There were no
differences in (11)C-labelled Pittsburgh compound B binding between
syndromes in any of the networks. Our data suggest that Alzheimer's
disease syndromes are associated with degeneration of specific
functional networks, and that fibrillar amyloid-β deposition explains at most a small amount of the clinico-anatomic heterogeneity in Alzheimer's disease.
Subscribe to:
Post Comments (Atom)
The secret of Eta Black by Ananya Sharma
The secret of Eta Black by Ananya Sharma A man sitting behind the bars named Eta black has no clue what is happening with him. He was searc...
Blog Archive
Pageviews
Live Traffic
Beta Amyloid Research
-
Beta Amyloid 25-35 : Abeta 25-35 :Amyloid Beta Peptide:25-35 : Beta Amyloid Peptides 25-35 : Research Paper of Abeta Peptide 25-35 Beta amyl...
-
Amyloid Beta Derived Diffusible Ligand: Beta Amyloid Ligands: Research Papers Sim PL, Heese K. Ligand-Dependent Activation of the Chi...
-
The amyloid hypothesis is initially compelling because the gene for the amyloid beta precursor APP is located on chromosome 21 , and pati...
-
Amyloid Cascade in Alzheimer’s Disease Review Article Shankar P S Address for correspondence: P S Shankar, Emeritus Professor ...
-
Subscribe to Amyloid et.al. by Email Phf1 Tau Antibody Guerrero R, Navarro P, Gallego E, Garcia-Cabrero AM, Avila J, Sanchez ...
-
Beta Amyloid Antibody Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA beta-amyloid(1-42) trimer immunization f...
-
Amyloid Research Fund: Amyloid Research Grants: Funding on Amyloid Reserach Program: Everyday Technologies for Alzheimer...
-
Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head ...
-
Alzheimer’s Research Papers Steiner RA, Hohmann JG, Holmes A, Wrenn CC, Cadd G, Juréus A, Clifton DK, Luo M, Gutshall M, M...
No comments:
Post a Comment